Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 12/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | F9 | P00740 | 1/20 | 0.36 |
| ▸ | F5 | P12259 | 1/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10902250 | 0.84 | MAPT (0.43) | MAPTADRA2CKDM4EMEN1ALDH1A1 | |
| SCHEMBL5395497 | 0.82 | F10 (0.43) | MAPTKDM4EF10F2F9 | |
| SCHEMBL16361760 | 0.82 | CYP3A4 (0.43) | MEN1ALDH1A1KMT2AF10 | |
| SCHEMBL1028976 | 0.78 | F10 (0.45) | F10F2F9F5CTRB1 | |
| SCHEMBL589410 | 0.76 | NR2E1 (0.44) | KDM4EALDH1A1F10F2F9 | |
| SCHEMBL62408 | 0.75 | CYP3A4 (0.57) | MAPTADRA2CKDM4EMEN1ALDH1A1 | |
| SCHEMBL10641492 | 0.75 | MAPT (0.47) | MAPTADRA2CKDM4EMEN1ALDH1A1 | |
| SCHEMBL6262265 | 0.75 | MAPT (0.50) | MAPTADRA2CKDM4EMEN1ALDH1A1 | |
| SCHEMBL8268238 | 0.74 | F10 (0.43) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6259586 | 0.74 | GAA (0.37) | MAPTADRA2CKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307431-B1 | EFFICIENT LIGAND-MEDIATED ULLMANN COUPLING OF ANILINES AND AZOLES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6541639-B2 | Condensation reaction of 2-fluoro-4-iodoaniline with 2-(N,N-dimethylamino) in presence of 8-hydroxyquinoline and copper iodide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020099225-A1 | Efficient ligand-mediated ullmann coupling of anilnies and azoles | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099225-A1 | Efficient ligand-mediated ullmann coupling of anilnies and azoles | F12, F2, UTS2R | MAPT 3253/4885ADRA2C 2234/4885KDM4E 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.